NEW YORK (GenomeWeb News) – Swiss firm Lonza said today that it has acquired cell research products firm amaxa for an undisclosed sum.
Lonza expects the acquisition to strengthen the cell discovery business of its Lonza Bioscience division, which supplies primary cells and serves a similar customer base to that of amaxa. Cologne, Germany-based amaxa’s Nucleofection technology is used to transfer DNA or RNA into cells that are considered difficult to transfect.
Lonza said that the acquisition will enhance the profit margins and growth rates for Lonza Bioscience. The deal is subject to regulatory approval and is expected to be completed early in the third quarter of this year.